

**Reference Number:** FOI202223/167  
**From:** Private Individual  
**Date:** 11 July 2022  
**Subject:** Number of patients who have received a list of treatments (for any disease)

**Q1** In the past 3 months (latest 3 months available) how many patients have received the following treatments (for any disease):

- a. Berinert (Human C1-esterase inhibitor)
- b. Cinryze (Human C1-esterase inhibitor)
- c. Orladeyo (berotralstat)
- d. Takhzyro (Lanadelumab)
- e. Ruconest (Recombinant human C1-esterase inhibitor)
- f. Firazyr (Icatibant injection)

**A1** a. Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.  
b - f: Information not held – we do not keep or supply this drug

**Q2** In the past 3 months (latest 3 months available) how many patients have received the following immunoglobulin treatments (for any disease):

- a. Cutaquig
- b. Cuvitru
- c. Gammanorm
- d. Gammaplex
- e. Gamunex
- f. Hizentra
- g. Hyqvia
- h. Intratect
- i. Iqymune
- j. Kiovig
- k. Privigen
- l. Octagam
- m. Panzyga
- n. Subgam

**A2** a. 6  
b. Information not held – we do not keep or supply this drug  
c. Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.  
d. Information not held – we do not keep or supply this drug  
e. Information not held – we do not keep or supply this drug  
f. 5  
g. Information not held – we do not keep or supply this drug  
h. 10  
i. Information not held – we do not keep or supply this drug  
j. Information not held – we do not keep or supply this drug  
k. Information exempted under Section 40: Personal data. Providing this information would likely identify individuals involved.

l. 9

m. Information not held – we do not keep or supply this drug

n. Information not held – we do not keep or supply this drug

The Trust has applied exemption Section 40(2) of the FOIA and is therefore withholding the information as disclosure which may identify an individual would breach their rights under the Data Protection Act 2018. The grounds for application of this exemption include:

- Any data relating to patients or staff is third party data, furthermore health data is classified as sensitive personal data within the Data Protection Act 2018. As such, Section 40 (2) of the FOIA applies along with the Trusts duty of confidentiality. Therefore under s.2 (3) (f) (ii) of the FOIA, there is an absolute exemption from disclosure on the grounds that it would contravene the First Data Protection Principle.
- The Trust has a duty under the Data Protection Act 2018 and specifically the First Data Protection Principle to ensure personal data regarding staff and patients is processed fairly and lawfully. Disclosure of such data which may identify an individual, either through the data alone or other data in conjunction with that data which may identify an individual would therefore breach this principle.
- The Data Protection Act 2018 defines sensitive personal data to include data relating to the “physical or mental health or condition” of a person. Any such information about specific individuals falls within this category and disclosure of such data including statistical data, with any potential likelihood of identification would breach the Data Protection Act 2018.